Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Clinical pharmacology and therapeutics (2014-01-25)

K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam, C A Prows, E D Kharasch, T C Skaar

PMID24458010

摘要

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

材料

货号

品牌

产品描述

M-005

Supelco

吗啡标准液溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

C-006

Supelco

可待因标准液溶液, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

M8777

Sigma-Aldrich

吗啡硫酸盐五水合物

M-030

Supelco

吗啡标准液溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

C-015

Supelco

可待因标准液溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

C5901

Supelco

可待因一水合物, analytical standard

M9524

Supelco

吗啡硫酸盐溶液, 1.0 mg/mL in methanol, drug standard